Last reviewed · How we verify
CBG002 CAR-T Cell Suspension — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
CBG002 CAR-T Cell Suspension (CBG002 CAR-T Cell Suspension) — Carbiogene Therapeutics Co. Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CBG002 CAR-T Cell Suspension TARGET | CBG002 CAR-T Cell Suspension | Carbiogene Therapeutics Co. Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CBG002 CAR-T Cell Suspension CI watch — RSS
- CBG002 CAR-T Cell Suspension CI watch — Atom
- CBG002 CAR-T Cell Suspension CI watch — JSON
- CBG002 CAR-T Cell Suspension alone — RSS
Cite this brief
Drug Landscape (2026). CBG002 CAR-T Cell Suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/cbg002-car-t-cell-suspension. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab